Anna Vilalta

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 6

Top Topics

Lipopolysaccharide Induced

Inflammatory Response

Amyotrophic Lateral Sclerosis

Top Venues

International journal of molecular sciences

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Pilar Pizcueta, Cristina Vergara, Marco Emanuele, Anna Vilalta, Laura Rodríguez-Pascau, Marc Martinell
Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate. International journal of molecular sciences 24 (4) (2023)
Pilar Pizcueta, Cristina Vergara, Marco Emanuele, Anna Vilalta, Laura Rodríguez-Pascau, Marc Martinell
Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate. International journal of molecular sciences 24 (4) (2023)
Pilar Pizcueta, Cristina Vergara, Marco Emanuele, Anna Vilalta, Laura Rodríguez-Pascau, Marc Martinell
Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate. International journal of molecular sciences 24 (4) (2023)
Pilar Pizcueta, Cristina Vergara, Marco Emanuele, Anna Vilalta, Laura Rodríguez-Pascau, Marc Martinell
Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate. International journal of molecular sciences 24 (4) (2023)
Pilar Pizcueta, Cristina Vergara, Marco Emanuele, Anna Vilalta, Laura Rodríguez-Pascau, Marc Martinell
Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate. International journal of molecular sciences 24 (4) (2023)
Laura Rodríguez-Pascau, Anna Vilalta, Marc Cerrada, Estefania Traver, Sonja Forss-Petter, Isabelle Weinhofer, Jan Bauer, Stephan Kemp, Guillem Pina, Sílvia Pascual, Uwe Meya, Patricia L Musolino, Johannes Berger, Marc Martinell, Pilar Pizcueta
The brain penetrant PPARγ agonist leriglitazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy. Science translational medicine 13 (596) (2021)